Quantifying UV-induced photodamage for longitudinal live-cell imaging applications of deep-UV microscopy.

Deep-UV microscopy enables high-resolution, label-free molecular imaging by leveraging biomolecular absorption properties in the UV spectrum. Recent advances in UV-imaging hardware have renewed interest in this technique for quantitative live cell imaging applications. However, UV-induced photodamage remains a concern for longitudinal dynamic imaging studies.

Non-invasive label-free imaging analysis pipeline for in situ characterization of 3D brain organoids.

Brain organoids provide a unique opportunity to model organ development in a system similar to human organogenesis in vivo. Brain organoids thus hold great promise for drug screening and disease modeling. Conventional approaches to organoid characterization predominantly rely on molecular analysis methods, which are expensive, time-consuming, labor-intensive, and involve the destruction of the valuable three-dimensional (3D) architecture of the organoids.

Label-free functional analysis of root-associated microbes with dynamic quantitative oblique back-illumination microscopy.

The increasing global demand for food, coupled with concerns about the environmental impact of synthetic fertilizers, underscores the urgency of developing sustainable agricultural practices. Nitrogen-fixing bacteria, known as diazotrophs, offer a potential solution by converting atmospheric nitrogen into bioavailable forms, reducing the reliance on synthetic fertilizers. However, a deeper understanding of their interactions with plants and other microbes is needed.

Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study.

Aim: To compare the efficacy and safety of saxagliptin/dapagliflozin and insulin glargine in people with latent autoimmune diabetes in adults (LADA).

Methods: In this phase 2b multicentre, open-label, comparator-controlled, parallel-group, non-inferiority study, we randomly assigned 33 people with LADA who had a fasting C-peptide concentration ≥0.2 nmol/L (0.